MedPath

Par Pharmaceutical, Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

38

Active:2
Completed:31

Trial Phases

3 Phases

Phase 1:31
Phase 2:1
Phase 3:5

Drug Approvals

155

FDA:155

Drug Approvals

Ibuprofen and famotidine

Approval Date
Mar 22, 2024
FDA

Clonazepam

Approval Date
Jan 30, 2024
FDA

Olanzapine and Fluoxetine

Approval Date
Jan 29, 2024
FDA

Varenicline

Approval Date
Jan 18, 2024
FDA

Allopurinol

Approval Date
Jan 8, 2024
FDA

Diltiazem Hydrochloride

Approval Date
Nov 20, 2023
FDA

Vasostrict

Approval Date
Nov 16, 2023
FDA

Methylprednisolone Acetate

Approval Date
Nov 3, 2023
FDA

Fluvoxamine Maleate

Approval Date
Oct 12, 2023
FDA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 16
  • Next

Clinical Trials

Distribution across different clinical trial phases (37 trials with phase data)• Click on a phase to view related trials

Phase 1
31 (83.8%)
Phase 3
5 (13.5%)
Phase 2
1 (2.7%)

Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermatitis

Phase 3
Completed
Conditions
Atopic Dermatitis
Interventions
First Posted Date
2017-09-29
Last Posted Date
2017-09-29
Lead Sponsor
Par Pharmaceutical, Inc.
Target Recruit Count
582
Registration Number
NCT03297502

Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy Tubes

Phase 3
Terminated
Conditions
Otitis Media in Patients With Tympanostomy Tubes
Interventions
First Posted Date
2013-11-26
Last Posted Date
2017-09-26
Lead Sponsor
Par Pharmaceutical, Inc.
Target Recruit Count
203
Registration Number
NCT01994642
Locations
🇺🇸

Birmingham Pediatrics, Birmingham, Alabama, United States

🇺🇸

Agave Clinical Ressearch, Mesa, Arizona, United States

🇺🇸

Arizona Center for Clinical Trials, Phoenix, Arizona, United States

and more 20 locations

A Bioequivalence Study of Two Ciprofloxacin/Dexamethasone Formulations in Patients With Otitis Externa

Phase 3
Terminated
Conditions
Otitis Externa
Interventions
First Posted Date
2013-07-29
Last Posted Date
2016-10-18
Lead Sponsor
Par Pharmaceutical, Inc.
Target Recruit Count
455
Registration Number
NCT01910155
Locations
🇺🇸

James Donivan Gordon, MD, Tucson, Arizona, United States

🇺🇸

Nea Baptist Clinic, Jonesboro, Arkansas, United States

🇺🇸

Applied Reserch Center, Little Rock, Arkansas, United States

and more 27 locations

Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fed Conditions

Phase 1
Completed
Conditions
To Determine Bioequivalence Under Fed Conditions
Interventions
First Posted Date
2011-06-27
Last Posted Date
2017-09-26
Lead Sponsor
Par Pharmaceutical, Inc.
Target Recruit Count
24
Registration Number
NCT01380496
Locations
🇨🇦

Anapharm Inc., Sainte-Foy, Quebec, Canada

Bioavailability Study of Dronabinol Capsules 10 mg Under Fasting Conditions

Phase 1
Completed
Conditions
To Determine Bioequivalence Under Fasting Conditions
Interventions
First Posted Date
2011-06-27
Last Posted Date
2011-06-27
Lead Sponsor
Par Pharmaceutical, Inc.
Target Recruit Count
69
Registration Number
NCT01380457
Locations
🇺🇸

BASi, Baltimore, Maryland, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 8
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath